Citations

Clear

4847 citation(s) found for "Yu, Eric".

Diagnosis of Attenuated Mucopolysaccharidosis VI: Clinical, Biochemical, and Genetic Pitfalls
Conboy, Erin , Jones, Amie, Barnett, Sarah , Klee, Eric W. , Lanpher, Brendan C. , Barnett, Sarah S, Vairo, Filippo Pinto e , Souza, Carolina Fischinger Moura de

Mayo Clinic

Pediatrics | November 23, 2018 | Volume: 142 | Issue: 6 | Pages: No page available

10.1542/peds.2018-0658 | PMID 30470723 Get It

Mucopolysaccharidosis type VI (MPS VI) is a clinically heterogeneous lysosomal disease, which can be divided into 2 main categories on the basis of age of onset and severity of symptoms. The diagnosis of the attenuated form is often delayed given subtle facial features rather than the typical coarse facial features of the classic form. Here, we discuss the difficulties in establishing the diagnosis of MPS VI on the basis of the report of 4 individuals. The most common signs and symptoms in our series were bone abnormalities and hip pain as initial manifestations and cardiac changes detected after follow-up studies. On the basis of our cohort and others worldwide, awareness of attenuated forms of MPS VI should be increased particularly among general practitioners, pediatricians, rheumatologists, orthopedists, ophthalmologists, and cardiologists. Moreover, these health care providers should be aware of the technical aspects involved in the molecular and biochemical diagnosis process so that they are aware how diagnostic errors may occur.
Psychological and Genetic Predictors of Pain Tolerance
Patanwala, Asad E. , Norwood, Charles , Steiner, Heidi E. , Morrison, Daniel, Li, May, Walsh, Keith, Martinez, M. Elena, Baker, Sarah E. , Snyder, Eric M., Karnes, Jason H. , Baker, Sarah E

Mayo Clinic

Clinical and Translational Science | November 23, 2018 | Volume: 12 | Issue: 2 | Pages: 189-195

10.1111/cts.12605 | PMID 30468309 Get It

Previous studies have shown associations between genetic polymorphisms and pain tolerance, but psychological evaluations are seldom measured. The objective of this study was to determine the independent effects of demographic, psychological, and genetic predictors of cold noxious pain tolerance. Healthy subjects (n = 89) completed the Pain Catastrophizing Scale (PCS) and Fear of Pain Questionnaire (FPQ‐III), underwent genotyping for candidate single nucleotide polymorphisms (SNPs), and completed a cold‐pressor test in a 1–2°C water bath for a maximum of 3 minutes. The primary outcome measure was pain tolerance, defined as the maximum duration of time subjects left their nondominant hand in the cold‐water bath. Cox proportional hazards regression indicated that female sex, Asian race, and increasing PCS and FPQ‐III scores were associated with lower pain tolerance. No candidate SNP was significantly associated with pain tolerance. Future genetic studies should include demographic and psychological variables as confounders in experimental pain models.
MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Whitwell, Jennifer L. , Tosakulwong, Nirubol , Botha, Hugo , Senjem, Matthew L. , Spychalla, Anthony J., Ahlskog, J. Eric , Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Schwarz, Christopher G. , Knopman, David S.

Mayo Clinic

Movement Disorders | November 23, 2018 | Volume: 34 | Issue: 1 | Pages: 105-113

10.1002/mds.27546 | PMID 30468693 Get It

AbstractBackgroundElevated uptake of the [18F]AV‐1451 tau‐PET ligand has been observed cross‐sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [18F]AV‐1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy.MethodsSixteen subjects with PSP underwent 2 serial [18F]AV‐1451 tau‐PET scans and 3‐Tesla MRI over 12 months and were age‐ and sex‐matched to 39 healthy controls with longitudinal [18F]AV‐1451 PET. Median [18F]AV‐1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo‐controlled treatment trials were calculated.ResultsRate of midbrain atrophy was significantly increased in PSP compared with controls. [18F]AV‐1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [18F]AV‐1451 measures. Smallest sample‐size estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [18F]AV‐1451 measures.Conclusions[18F]AV‐1451 tau‐PET measures increase over time in subjects with PSP, but longitudinal [18F]AV‐1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials. © 2018 International Parkinson and Movement Disorder Society
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
Qu, Xiaoyu , Braziel, Rita M., Passerini, Verena , Leonard, John P. , Smith, Sonali M. , Kridel, Robert , Press, Oliver W. , Weigert, Oliver , Friedberg, Jonathan W. , Fang, Min , Press, Oliver , Li, Hongli , Rimsza, Lisa M. , Hsi, Eric D. , Kridel, Robert , LeBlanc, Michael

Mayo Clinic

Blood | November 19, 2018 | Volume: 133 | Issue: 1 | Pages: 81-93

10.1182/blood-2018-07-865428 | PMID 30446494 Get It

Abstract Although recent advances in molecular genetics have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIPI score, the impact on treatment has been limited. We aimed to assess the prognostic significance of copy-number aberrations (CNAs) and copy-neutral loss of heterozygosity (cnLOH) identified by chromosome genomic-array testing (CGAT) at FL diagnosis using prospectively collected clinical trial specimens from 255 patients enrolled in the SWOG study S0016. The impact of genomic aberrations was assessed for early progression (progressed or died within 2 years after registration), progression-free survival (PFS), and overall survival (OS). We showed that increased genomic complexity (ie, the total number of aberration calls) was associated with poor outcome in FL. Certain chromosome arms were critical for clinical outcome. Prognostic CNAs/cnLOH were identified: whereas early progression was correlated with 2p gain (P = .007; odds ratio [OR] = 2.55 [1.29, 5.03]) and 2p cnLOH (P = .005; OR = 10.9 [2.08, 57.2]), 2p gain specifically encompassing VRK2 and FANCL predicted PFS (P = .01; hazard ratio = 1.80 [1.14, 2.68]) as well as OS (P = .005; 2.40 [1.30, 4.40]); CDKN2A/B (9p) deletion correlated with worse PFS (P = .004, 3.50 [1.51, 8.28]); whereas CREBBP (16p) (P < .001; 6.70 [2.52, 17.58]) and TP53 (17p) (P < .001; 3.90 [1.85, 8.31]) deletion predicted worse OS. An independent cohort from the m7-FLIPI study was explored, and the prognostic significance of aberration count, and TP53 and CDKN2A/B deletion were further validated. In conclusion, assessing genomic aberrations at FL diagnosis with CGAT improves risk stratification independent of known clinical parameters, and provides a framework for development of future rational targeted therapies.
Extension of the mutational and clinical spectrum of SOX2 related disorders: Description of six new cases and a novel association with suprasellar teratoma
Blackburn, Patrick R. , Chacón‐Camacho, Oscar F. , Ortiz‐González, Xilma R. , Reyes-Rosales, Mariana , López-Uriarte, Graciela Arelí , Zarei, Shabnam , Bhoj, Elizabeth , Pérez‐Solórzano, Sofía, Murphree, Marine I., Nava, Jessica, Cortés‐González, Vianney , Parisi, Joseph E. , Villanueva‐Mendoza, Cristina , Tirado‐Torres, Iris G., Klee, Eric W. , Pichurin, Pavel N. , Bhoj, Elizabeth J , Zenteno, Juan C , Vaubel, Rachael A. , Li, Dong

Mayo Clinic

American Journal of Medical Genetics Part A | November 19, 2018 | Volume: 176 | Issue: 12 | Pages: 2710-2719

10.1002/ajmg.a.40644 | PMID 30450772 Get It

SOX2 is a transcription factor that is essential for maintenance of pluripotency and has several conserved roles in early embryonic development. Heterozygous loss‐of‐function variants in SOX2 are identified in approximately 40% of all cases of bilateral anophthalmia/micropthalmia (A/M). Increasingly SOX2 mutation‐positive patients without major eye findings, but with a range of other developmental disorders including autism, mild to moderate intellectual disability with or without structural brain changes, esophageal atresia, urogenital anomalies, and endocrinopathy are being reported, suggesting that the clinical phenotype associated with SOX2 loss is much broader than previously appreciated. In this report we describe six new cases, four of which carry novel pathogenic SOX2 variants. Four cases presented with bilateral anophthalmia in addition to extraocular involvement. Another individual presented with only unilateral anophthalmia. One individual did not have any eye findings but presented with a suprasellar teratoma in infancy and was found to have the recurrent c.70del20 mutation in SOX2 (c.70_89del, p.Asn24Argfs*65). This is this first time this tumor type has been reported in the context of a de novo SOX2 mutation. Notably, individuals with hypothalamic hamartomas and slow‐growing hypothalamo‐pituitary tumors have been reported previously, but it is still unclear how SOX2 loss contributes to their formation.
Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease
Kennedy, Cassie C. , Novotny, Paul J. , Wise, Robert A. , Sciurba, Frank C. , Benzo, Roberto P. , Hoffman, Eric A. , Reardon, Michael J. , Mullan, Brian F. , Sieren, Jessica C. , Kennedy, Cassie C , Wise, Robert , Hoffman, Eric A , Reardon, Michael J , LeBrasseur, Nathan K.

Mayo Clinic

Annals of the American Thoracic Society | November 15, 2018 | Volume: 16 | Issue: 2 | Pages: 217-224

10.1513/annalsats.201803-175oc | PMID 30433830 Get It

Abstract Rationale Frailty represents an increased vulnerability to adverse health outcomes. The frailty phenotype conceptual model (three or more patient attributes of wasting, exhaustion, low activity, slowness, and weakness) is associated with increased morbidity and mortality in geriatric populations. Objectives Our objective was to describe the risks associated with frailty in patients with chronic obstructive pulmonary disease. Methods Data from the National Emphysema Treatment Trial (NETT) were retrospectively analyzed. The frailty phenotype conceptual model was operationalized as three or more frailty parameters (a body mass index decrease of ≥5% over 12 months, self-reported exhaustion, low 6-minute walk distance, or physical activity or respiratory muscle strength in the lowest quartile). Frail participants were compared with participants with two or fewer frailty parameters. Participants were followed starting 12 months after NETT randomization (to minimize surgical effect) for 24 months. Univariate, multivariate, Kaplan-Meier, and Cox proportional hazard analyses were performed, adjusting for treatment arm, age, modified Medical Research Council dyspnea scale, sex, and baseline forced expiratory volume in 1 second (FEV1). Multiple imputation was used for missing values. Results The participants (N = 902) were predominantly white (94.5%) males (59.5%), with a median age of 67 years (interquartile range, 63–70 yr) and a median FEV1% predicted of 26 (interquartile range, 20–33). Six percent of the participants (95% confidence interval [CI], 4.5 to 7.6) were frail. The incidence rate of frailty was 6.4 per 100 person-years. Frail participants reported significantly worse disease-specific and overall quality of life by St. George’s Respiratory Questionnaire total score (mean difference of 11.6; 95% CI, 7.6 to 15.6; P < 0.001), mental composite on Medical Outcomes Survey Short Form-36 (mean difference −6.8; 95% CI, −10.0 to −3.6; P < 0.001), and physical composite scores on Medical Outcomes Survey Short Form-36 (mean difference −16.7; 95% CI, −21.3 to −12.1; P = 0.001). Frail participants had an increased rate of hospitalization (adjusted hazard ratio, 1.6; 95% CI, 1.1 to 2.5; P = 0.02) and an adjusted increase in hospital use of 8.0 days (95% CI, 4.4 to 11.6; P < 0.001) compared with nonfrail participants. Frail participants had a higher mortality rate (adjusted hazard ratio, 1.4; 95% CI, 0.97 to 2.0; P = 0.07). Conclusions Among adults with chronic obstructive pulmonary disease, our measure of frailty (modified from the Fried frailty phenotype) was associated with incident and longer-duration hospitalization, and with poor quality of life.
Acute ischemic stroke secondary to cardiac embolus of a ‘foreign body’ material after a redo sternotomy for mitral valve replacement: A case report
Fitzgerald, Seán , Rizvi, Asim , Williamson, Eric E. , Doyle, Karen , Kallmes, David F. , Brinjikji, Waleed , Dai, Daying , Fitzgerald, Seán , Lanzino, Giuseppe

Mayo Clinic

Interventional Neuroradiology | November 14, 2018 | Volume: 25 | Issue: 2 | Pages: 208-211

10.1177/1591019918810538 | PMID 30428742 Get It

Summary Cardiac surgery has been shown to be associated with increased risk of acute ischemic stroke. This report presents a case of a successful mechanical embolectomy procedure to treat a patient for an acute ischemic stroke, which was caused by the cardiac embolization of a ‘foreign body’ containing debris following a redo sternotomy procedure for mitral valve replacement and tricuspid valve annuloplasty.
Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer
Gerke, Travis , Beltran, Himisha , Lee, Gwo‐Shu Mary , Karnes, R. Jeffrey , Klein, Eric A. , Davicioni, Elai , Yousefi, Kasra, Ross, Ashley E. , Börnigen, Daniela , Mucci, Lorelei A. , Sweeney, Christopher J. , Davicioni, Elai , Klein, Eric A , Sweeney, Christopher , Wang, Xiaodong , Sboner, Andrea , Huttenhower, Curtis , Trock, Bruce J

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 12, 2018 | Volume: 28 | Issue: 3 | Pages: 584-590

10.1158/1055-9965.epi-18-0667 | PMID 30420441 Get It

Abstract Background: Inflammation is linked to prostate cancer progression and is mediated by NF-κB. Tristetraprolin is a key node of NF-κB activation and we investigated its biological and prognostic role in lethal prostate cancer. Methods: In vitro assays assessed the function of tristetraprolin and the association between low mRNA tristetraprolin levels and lethal prostate cancer (metastatic disease or death) was assessed across independent prostatectomy cohorts: (i) nested case-control studies from Health Professionals Follow-up Study and Physicians’ Health Study, and (ii) prostatectomy samples from Cleveland Clinic, Mayo Clinic, Johns Hopkins and Memorial Sloan Kettering Cancer Center. Tristetraprolin expression levels in prostatectomy samples from patients with localized disease and biopsies of metastatic castration–resistant prostate cancer (mCRPC) were assessed in a Cornell University cohort. Results: In vitro tristetraprolin expression was inversely associated with NF-κB–controlled genes, proliferation, and enzalutamide sensitivity. Men with localized prostate cancer and lower quartile of tumor tristetraprolin expression had a significant, nearly two-fold higher risk of lethal prostate cancer after adjusting for known clinical and histologic prognostic features (age, RP Gleason score, T-stage). Tristetraprolin expression was also significantly lower in mCRPC compared with localized prostate cancer. Conclusions: Lower levels of tristetraprolin in human prostate cancer prostatectomy tissue are associated with more aggressive prostate cancer and may serve as an actionable prognostic and predictive biomarker. Impact: There is a clear need for improved biomarkers to identify patients with localized prostate cancer in need of treatment intensification, such as adjuvant testosterone suppression, or treatment de-intensification, such as active surveillance. Tristetraprolin levels may serve as informative biomarkers in localized prostate cancer.
Infographic: Replacing failed reverse shoulder arthroplasties as a reliable revision approach
Wagner, Eric R. , Cofield, Robert H. , Sperling, John W. , Wagner, Eric R , Hevesi, Mario , Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

The Bone & Joint Journal | November 12, 2018 | Volume: 100-B | Issue: 11 | Pages: 1491-1492

10.1302/0301-620x.100b11.bjj-2018-1139 | PMID 30418056 Get It

Can a reverse shoulder arthroplasty be used to revise a failed primary reverse shoulder arthroplasty?
Wagner, Eric R. , Cofield, Robert H. , Sperling, John W. , Wagner, Eric R , Hevesi, Mario , Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

The Bone & Joint Journal | November 12, 2018 | Volume: 100-B | Issue: 11 | Pages: 1493-1498

10.1302/0301-620x.100b11.bjj-2018-0226.r2 | PMID 30418055 Get It

Aims Patients with a failed reverse shoulder arthroplasty (RSA) have limited salvage options. The aim of this study was to determine the outcome of revision RSA when used as a salvage procedure for a failed primary RSA. Patients and Methods We reviewed all revision RSAs performed for a failed primary RSA between 2006 and 2012, excluding patients with a follow-up of less than two years. A total of 27 revision RSAs were included in the study. The mean age of the patients at the time of revision was 70 years (58 to 82). Of the 27 patients, 14 (52% were female). The mean follow-up was 4.4 years (2 to 10). Results Six patients (22%) developed complications requiring further revision surgery, at a mean of 1.7 years (0.1 to 5.3) postoperatively. The indication for further revision was dislocation in two, glenoid loosening in one, fracture of the humeral component in one, disassociation of the glenosphere in one, and infection in one. The five-year survival free of further revision was 85%. Five additional RSAs developed complications that did not need surgery, including dislocation in three and periprosthetic fracture in two. Overall, patients who did not require further revision had excellent pain relief, and significant improvements in elevation and external rotation of the shoulder (p < 0.01). The mean postoperative American Shoulder and Elbow Surgeons (ASES), and simple shoulder test (SST) scores were 66 and 7, respectively. Radiological results were available in 26 patients (96.3%) at a mean of 4.3 years (1.5 to 9.5). At the most recent follow-up, six patients (23%) had glenoid lucency, which were classified as grade III or higher in three (12%). Smokers had a significantly increased risk of glenoid lucency (p < 0.01). Conclusion Revision RSA, when used to salvage a failed primary RSA, can be a successful procedure. At intermediate follow-up, survival rates are reasonable, but dislocation and glenoid lucency remain a concern, particularly in smokers. Cite this article: Bone Joint J 2018;100-B:1493–98.